PIP: Depot medroxyprogesterone acetate (DMPA) generally injected in doses of 150 mg every 3 months, is offered in the official family planning program of Mexico. The study purpose was to assess the impact of attitudes toward DMPA of medical and paramedical family planning workers on the frequency of prescription and acceptance of DMPA in the national family planning program. A 21-item multiple choice mail questionnaire was returned by 644 persons including 279 physicians, 257 nurses, and 104 social workers from Mexico City and 24 of the 31 states, a response rate of 55.6%. 338 of the respondents worked in health centers, 274 had worked in family planning for less than 1 year, and 427 were female. 365 had previous experience with DMPA. 458 knew the correct quarterly dose. Only 66 persons (10.8%) frequently prescribed DMPA, while 373 (61.1%) occasionally prescribed it and 169 (27.7%) never did so. 582 persons knew of at least 2 other injectable contraceptives. Among side effects, 423 persons mentioned frequent amenorrhea, 267 frequent bleeding, and 329 a reduction of future fertility. 203 mentioned that it did not affect lactation. 361 noted that it has high contraceptive efficacy. 439 considered administration of DMPA simple and 235 thought it was a good contraceptive. Asked what type of injectable contraceptive they preferred, 148 selected a combined monthly injection, 125 selected a progestogen every 84 days, and 115 selected DMPA. 416 considered their information on DMPA to have come from scientific sources. Medical journals were cited by 156, training courses by 271, and commercial promotions by pharmaceutical companies by 236. 612 persons (97.0%) felt that more training on DMPA use should be provided for family planning personnel, and 594 (94.7%) felt that users should receive more information. Discrepancies in the knowledge of DMPA among family planning workers indicate the need for improved training of new family planning workers and for continuing education of experienced workers.^ieng